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MaOBJECTIVES This study sought to determine whether epicardial adipose tissue (EAT) volume predicts the progression
of coronary artery calciﬁcation (CAC) score in the general population.
BACKGROUND EAT predicts coronary events and is suggested to inﬂuence the development of atherosclerosis.
METHODS We included 3,367 subjects (mean age 59  8 years; 47% male) from the population-based Heinz
Nixdorf Recall study without known coronary artery disease at baseline. CAC was quantiﬁed from noncontrast cardiac
electron beam computed tomography at baseline and after 5 years. EAT was deﬁned as fat volume inside the
pericardial sac and was quantiﬁed from axial computed tomography images. Association of EAT volume with CAC
progression (log[CAC(follow-up) þ 1]  log[CAC(baseline) þ 1]) was depicted as percent progression of CAC þ 1 per
SD of EAT.
RESULTS Subjects with progression of CAC above the median had higher EAT volume than subjects with less CAC
change (101.1  47.1 ml vs. 84.4  43.4 ml; p < 0.0001). In regression analysis, 6.3% (95% conﬁdence interval [CI]:
2.3% to 10.4%; p ¼ 0.0019) of progression of CAC þ 1 was attributable to 1 SD of EAT, which persisted after
adjustment for risk factors (6.1% [95% CI: 1.2% to 11.2%]; p ¼ 0.014). For subjects with a CAC score of >0 to #100,
progression of CAC þ 1 by 20% (95% CI: 11% to 31%; p < 0.0001) was attributable to 1 SD of EAT. Effect sizes
decreased with CAC at baseline, with no relevant link for subjects with a CAC score $400 (0.2% [95% CI: 3.5% to
4.2%]; p ¼ 0.9). Likewise, subjects age <55 years at baseline showed the strongest association of EAT with CAC
progression (20.6% [95% CI: 9.7% to 32.5%]; p < 0.0001). Interestingly, the effect of EAT on CAC progression was
more pronounced in subjects with low body mass index (BMI), and decreased with degree of adiposity (BMI #25 kg/m2:
19.8% [95% CI: 9.2% to 31.4%]; p ¼ 0.0001, BMI >40 kg/m2: 0.8% [95% CI: 26.7% to 38.9%]; p ¼ 0.96).
CONCLUSIONS EAT is associated with the progression of CAC, especially in young subjects and subjects with low CAC
score, suggesting that EAT may promote early atherosclerosis development. (J Am Coll Cardiol Img 2014;7:909–16)
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ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
CAC = coronary artery
calciﬁcation
CI = conﬁdence interval
CT = computed tomography
EAT = epicardial adipose tissue
HDL = high-density lipoprotein
LDL = low-density lipoprotein
MV = multivariate
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910E picardial adipose tissue (EAT) is asso-ciated with cardiovascular risk fac-tors, coronary artery plaque burden,
and prevalent cardiovascular disease (1–3).
Moreover, it is associated with future cardio-
vascular events independent of traditional
cardiovascular risk factors, suggesting that
EAT may inﬂuence atherosclerosis develop-
ment, potentially via its inﬂammatory modu-
lating effect (4–7).
Besides a controversial association with
calciﬁc plaque burden (1,6), a strong associ-ation of EAT with noncalciﬁed plaque components
was reported (2,8). Together with a more pronounced
association of EAT with future coronary events in
subjects with no or low coronary artery calciﬁcation
(CAC) (6), these results support the hypothesis of a
mechanistic role of EAT in the early phase of
atherosclerosis. First studies suggested that EAT
may promote CAC progression in selected cohorts
(9–11). However, to date, data from an asymptomatic
general population cohort to conﬁrm these results is
lacking. Therefore, the aim of the current analysis
was to determine whether EAT predicts progression
of CAC in a European population-based cohort over
a period of 5 years.SEE PAGE 917METHODS
STUDY PARTICIPANTS. The Heinz Nixdorf Recall
study is a population-based, prospective cohort study
designed to assess the predictive value of novel
markers for risk stratiﬁcation in addition to tradi-
tional cardiovascular risk factors. The participants
(45 to 75 years of age) were randomly selected from
mandatory lists of residence from the 3 adjacent cities
of Bochum, Essen, and Mülheim, Germany, and were
enrolled between 2000 and 2003, with a recruitment
efﬁcacy of 55.8%. Details for recruitment and study
design have been previously published (12,13). For
this analysis, we excluded subjects with known
coronary artery disease at baseline (n ¼ 327) or revas-
cularization between baseline and follow-up exami-
nation (n ¼ 154). Additionally, 159 subjects died before
follow-up examination, and 407 subjects did not par-
ticipate in the follow-up examination. A total of 246
subjects were excluded due to missing CAC score at
baseline or follow-up examination. EAT volume or 1 or
more risk factors were missing in 154 subjects, result-
ing in a total cohort of 3,367 subjects. All participants
provided written informed consent, and the study
was approved by the institutional ethics committee.CARDIOVASCULAR RISK FACTOR ASSESSMENT.
Traditional cardiovascular risk factors were measured
at baseline, with details being previously published
(14). Body mass index (BMI) was calculated on the
basis of direct measurements as the weight divided
by the square of height. Waist circumference was
measured at the leanest circumference between the
costal arch and the iliac crest. Blood pressure was
measured using an oscillometric method (Omron,
Hoofddorp, the Netherlands). The mean value of
the second and third of 3 measurements taken
at least 2 min apart were used. Standardized
enzymatic methods were used to determine serum
high-density lipoprotein (HDL) cholesterol and low-
density lipoprotein (LDL) cholesterol. Diabetes was
deﬁned as a history of diabetes, being on medical
treatment, or on the basis of blood glucose levels, as
previously published (15). Smoking history was
classiﬁed as current smokers, former smokers, and
no history of smoking, assessed by computer-
assisted interview (16). A positive family history of
coronary heart disease was deﬁned as premature
nonfatal or fatal coronary heart disease diagnosis. An
event was considered premature if it occurred before
55 years of age in men and before 65 years of age in
women (17). If ancestors were unknown or died early
(e.g., in the Second World War), or if information
was missing, subjects were classiﬁed as not having
positive family history.
CARDIAC COMPUTED TOMOGRAPHY. As part of the
study, subjects underwent cardiac computed tomog-
raphy (CT) for quantiﬁcation of CAC. Electron beam
computed tomography scans were performed utiliz-
ing a C-100 or C-150 scanner (GE Imatron, South San
Francisco, California) without the use of contrast
media. Imaging was prospectively triggered at 80% of
the RR interval, and contiguous 3-mm-thick slices
from the right pulmonary artery to the apex of the
heart were obtained at an image acquisition time of
100 ms. Follow-up imaging was performed with
identical scanning protocol, using an Imatron C-150
scanner. CAC was deﬁned as a focus of at least 4
contiguous pixels with a CT density >130 Hounsﬁeld
units (HU) and quantiﬁed using the Agatston
method (18). Participants and physicians remained
unaware of the CAC scoring results of the baseline
examination.
EPICARDIAL FAT VOLUME QUANTIFICATION. Epi-
cardial fat volume was assessed using a dedicated
workstation. The pericardium was manually traced
from the right pulmonary artery to the diaphragm to
determine a region of interest. Within the region of
interest, fat was deﬁned as pixels within a window
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911of 195 to 45 HU and a window center of 120 HU.
Overall, only pixels with HUs equivalent to fat within
the pericardial sac were counted as epicardial adipose
tissue. Reproducibility was tested in 100 cases and
was excellent (intraclass correlation coefﬁcient
[ICC] ¼ 0.988, p < 0.0001 for interobserver and in-
traclass correlation coefﬁcient ¼ 0.996, p < 0.0001 for
intraobserver variability). Details of EAT quantiﬁca-
tion have been previously described in detail (6).
STATISTICAL ANALYSIS. Continuous variables are
reported as mean  SD for normally distributed data
or median and quartiles (Q1; Q3) for non-normally
distributed data. Discrete variables are given in fre-
quency and percent. EAT was normally distributed,
whereas logarithmic transformation of CAC score (log
[CAC þ 1]) was performed to normalize the CAC dis-
tribution. Correlation of EAT volume with BMI and
waist circumference was calculated using the Pearson
correlation coefﬁcient. The 2-sided Mann-Whitney
U test was used to assess differences in CAC
comparing ﬁrst versus fourth quartile of EAT. CAC
progression was calculated as the difference of
logarithmic CAC scores at follow-up and baseline (log
[CAC þ 1][t1] – log[CAC þ 1][t0]). Using this approach,
CAC progression was normally distributed. Spearman
correlation coefﬁcient revealed no relevant link
among variation of time between both scans and
progression of CAC (r ¼ 0.016, p ¼ 0.36). EAT volumes
between groups of CAC progression above versus
below the median were compared using the 2-sided
Student t test. Linear regression analysis was per-
formed to investigate unadjusted and multivariable-
adjusted association of EAT with CAC progression
using the following models: 1) unadjusted; 2) BMI-
adjusted; 3) BMI, age, and sex-adjusted; 4) multi-
variable analysis, including model 3 þ systolic
blood pressure, antihypertensive medication, LDL
cholesterol, HDL cholesterol, lipid-lowering medica-
tion, triglycerides, diabetes, present smoking, and
former smoking; and 5) including model 4 and posi-
tive family history of premature coronary heart dis-
ease. As an additional analysis, we calculated the
association of EAT with CAC progression with base-
line CAC score (as log[CAC þ 1]) included in the
model. Parameter estimates are given per sex-speciﬁc
SD of EAT volume as previously described for EAT,
leading to easy-to-understand effect sizes (3,6). In
addition, identical regression analyses were per-
formed using waist circumference instead of BMI in
all models. Besides sex-pooled analysis, sex-speciﬁc
analysis was also performed, including a test of
interaction between EAT and sex. Further, regression
analysis was stratiﬁed by CAC score at baseline, usingthe following CAC groups: 0, >0 to <100, $100
to <400, and $400. In addition to the progression of
log-transformed CAC scores, we calculated regression
analyses of EAT with the difference of square root of
CAC at follow-up and the square root of CAC at
baseline, using identical models. Also, we stratiﬁed
regression analysis by age at baseline using the
following age groups: <55, $55 to 65, and $65 years of
age. To assess the effect in different BMI groups and
rule out modeling effects of BMI and EAT due to their
correlation, we further investigated the association of
EAT with CAC progression stratiﬁed by BMI groups in
unadjusted regression analysis (#25, >25 to #30, >30
to #40, and >40 kg/m2). Risk factor–adjusted (model
4) regression analysis was performed in the following
groups: #25 and >25 kg/m2. To conﬁrm the result of a
positive association of EAT volume with CAC pro-
gression, we tested the association of EAT with CAC
at follow-up when controlling for CAC at baseline in
the model. Again, further adjustment for age, sex,
and BMI as well as multivariable adjustment, ancil-
lary to CAC at baseline was performed. Within the
subset of subjects with CAC score ¼ 0 at baseline, we
determined the onset of CAC as CAC >0 at follow-up
examination. The difference of EAT volume between
subjects with and without onset of CAC was com-
pared using the 2-sided Student t test. Successive
logistic regression analysis was performed to deter-
mine the association of EAT with onset of CAC, using
the same models as for the regression analysis of
progression of CAC. Again, analysis was stratiﬁed
by age groups. All analyses were performed using
SAS software (version 9.2, SAS Institute Inc., Cary,
North Carolina). A p value <0.05 indicated statistical
signiﬁcance.
RESULTS
Overall, 3,367 subjects (mean age 59  8 years; 47%
male) were included in this analysis, with detailed
characteristics of the study cohort depicted in
Table 1. Median CAC score at baseline was 7.0
(quartile [Q] 1: 0.0; Q3: 88.2) and 25.8 (Q1: 0.0; Q3:
190.0) after a follow-up period of 5.1  0.3 years.
EAT was strongly correlated with both BMI (r ¼ 0.48;
p< 0.0001) and waist circumference (r ¼ 0.64;
p < 0.0001), whereas BMI and waist circumference
showed the strongest correlation (r ¼ 0.80; p <
0.0001). Subjects with progression of CAC above the
median had higher EAT volume then subjects with
CAC change below the median (101.1  47.1 vs.
84.4  43.4; p < 0.0001).
CAC score at both baseline and follow-up exami-
nation increased with quartiles of EAT (Figure 1).
TABLE 1 Baseline Characteristics (N ¼ 3,367)
Age, yrs 58.9  7.6
Male 1,572 (46.7)
BMI, kg/m2 27.6  4.4
Waist circumference, cm 93.0  12.7
Systolic blood pressure, mm Hg 131.7  20.1
Diastolic blood pressure, mm Hg 81.3  10.6
Antihypertensive medication 1,017 (30.2)
LDL cholesterol, mg/dl 146.1  35.6
HDL cholesterol, mg/dl 59.3  17.2
Lipid-lowering medication 298 (9.5)
Triglycerides, mg/dl 144.9  98.5
Diabetes 373 (11.1)
Smoking
Current 745 (22.1)
Former 1,145 (34.0)
Never 1,477 (43.9)
CAC score at baseline 7.0 (0.0; 88.2)
CAC score at follow-up 25.8 (0.0; 190.0)
EAT volume 92.8  46.0
Values are mean  SD, n (%), or median (quartile 1; quartile 3).
BMI ¼ body mass index; CAC ¼ coronary artery calciﬁcation; EAT ¼ epicardial
adipose tissue; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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912When stratifying by CAC group at baseline, we
observed signiﬁcantly higher CAC scores at follow-
up for all CAC groups except for CAC $400 (CAC ¼
0: n¼ 1,224; CAC >0 to <100: n ¼ 1,335; CAC $100
to <400: n ¼ 541; CAC $400: n ¼ 267).3125
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FIGURE 1 CAC Score as Stratiﬁed by Quartile of EAT
Epicardial adipose tissue (EAT) quartile-speciﬁc coronary artery calciﬁca
follow-up as well as CAC score at follow-up, stratiﬁed by CAC group at ba
follow-up with increasing quartile (Q) of EAT (Q1 to Q4). 2-sided Mann
versus Q4 of EAT.EAT VOLUME AND CAC PROGRESSION. In regression
analysis, EAT showed signiﬁcant association with
progression of CAC as demonstrated as percent
change in (CAC þ 1) with 6.3% (95% conﬁdence in-
terval [CI]: 2.3% to 10.4%; p ¼ 0.0019) progression
attributable to 1 SD of EAT volume. This effect was
even strengthened when further adjusting for BMI
(14.2% [95% CI: 9.2% to 19.3%]; p < 0.0001) and
remained statistically signiﬁcant after additional
adjustment for age and sex (9.2% [95% CI: 4.7% to
14.7%]; p < 0.0001) as well as traditional cardiovas-
cular risk factors (6.1% [95% CI: 1.2% to 11.2%];
p ¼ 0.014). Similar results were observed when
further adjusting for baseline CAC score (detailed
data not shown). Results remained unchanged when
additionally adjusting for positive family history of
premature coronary heart disease (6.1% [95% CI: 1.2%
to 11.2%]; p ¼ 0.014). When using waist circumference
instead of BMI in the model, similar results were
observed (waist circumference adjusted: 11.5% [95%
CI: 6.5% to 16.8%], percent change in CAC þ 1;
p < 0.0001; multivariate [MV] adjusted: 7.8% [95% CI:
2.7% to 13.2%]; p ¼ 0.0024).
Figure 2 demonstrates the association of EAT with
progression of CAC, stratiﬁed by CAC score at
baseline. In age, sex, and BMI–adjusted models, 1 SD
of EAT was associated with 20% (95% CI: 11% to
31%; p < 0.0001) progression of CAC þ 1 in subjects
with a low CAC score (>0 to <100). A lowerFollow-up
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
p < 0.0001
p = 0.015
p = 0.16
2
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FIGURE 2 EAT-Attributable Progression in CAC by CAC Group at Baseline
Regression analysis for the association of EAT volume with CAC progression as stratiﬁed by CAC score at baseline, revealing that those subjects
with low CAC score at baseline showed highest EAT-attributable CAC progression. *Multivariate (MV) adjustment included age, sex, body mass
index (BMI), systolic blood pressure, antihypertensive medication, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol,
lipid-lowering medication, triglyceride, diabetes, present smoking, and former smoking. Abbreviations as in Figure 1.
TABLE 2 Age-Group–Speciﬁc Linear Regression Analysis for the Association of
EAT Volume With Progression of CAC
Age Group, yrs n
Sex and BMI–Adjusted MV-Adjusted*
% progression in CAC þ 1
(95% CI) p Value
% progression in CAC þ 1
(95% CI) p Value
<55 1,136 27.7 (16.7–40.0) <0.0001 19.8 (8.9–31.7) 0.0002
$55–<65 1,372 6.2 (1.0–13.9) 0.09 2.5 (4.8–10.4) 0.5
$65 859 0.6 (6.6–8.5) 0.9 3.9 (7.2–7.9) 0.98
Depicted as % progression of CAC þ 1 per each SD of EAT. *Multivariate (MV) adjustment included sex,
BMI, systolic blood pressure, antihypertensive medication, LDL cholesterol, HDL cholesterol, lipid-lowering
medication, triglycerides, diabetes, present smoking, and former smoking.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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913association was found for subjects with a CAC
of $100 to <400 with 8% (95% CI: 3% to 13%; p ¼
0.003) progression of CAC þ 1 attributable to EAT. In
contrast, CAC $400 showed no relevant association
of EAT with CAC progression when adjusting for
age, sex, and BMI (0.2% [95% CI: 3.5% to 4.1%];
p ¼ 0.90). Similar results were observed when
further adjusting for established cardiovascular risk
factors, with 14% (95% CI: 5% to 24%) progression
of CAC þ 1 attributable to 1 SD of EAT in subjects
with a CAC of >0 to <100 at baseline (Figure 2).
Interestingly, subjects with a CAC of 0 at baseline
showed no association of EAT with CAC progression
(age, sex, and BMI–adjusted: 3.3% [95% CI: 5.4%
to 12.9%]; p ¼ 0.47; MV-adjusted: 2.2% [95%
CI: 10.9% to 7.3%]; p ¼ 0.6). Using the difference
of the square root of CAC at follow-up and at
baseline, statistical signiﬁcance was observed for
identical models as for the calculation of percent of
change of CAC þ 1 (detailed data not shown).
Table 2 depicts the association of EAT with
progression of CAC, stratiﬁed by age at baseline
examination (<55, $55 to <65, and $65 years of
age). For subjects below 55 years of age, a strong
link with progression of CAC was observed in
unadjusted and fully adjusted models. In contrast,
no relevant association was observed for
subjects $55 years of age (Table 2).To further assess the interaction of BMI and EAT on
CAC progression, we determined the association of
EAT with CAC progression in different BMI groups.
Although association of EAT with CAC progression
was strongest in subjects with BMI #25 kg/m2, with
approximately 20% progression of CAC þ 1 per SD of
EAT volume, this association decreased with
increasing BMI, with no link between EAT and CAC
progression in subjects with adiposity III (BMI >40
kg/m2) (Table 3). These ﬁndings were conﬁrmed in
multivariable analysis, where EAT was associated
with CAC progression only in subjects with BMI #25
kg/m2 (13.1% [95% CI: 1.9% to 25.6%]; p ¼ 0.02),
whereas no relevant link was found for overweight
TABLE 3 BMI-Speciﬁc Unadjusted Linear Regression Analysis
for the Association of EAT Volume With Progression of CAC
BMI, kg/m2 n
% Progression in CAC þ 1
(95% CI) p Value
#25 980 19.8 (9.2–31.4) 0.0001
>25–#30 1,566 11.9 (5.0–19.3) 0.0005
>30–#40 783 9.3 (0.8–18.5) 0.032
>40 38 0.8 (26.7–38.9) 0.96
Depicted as % progression of CAC þ 1 per each SD of EAT.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
TABLE 4 Logistic Re
of CAC in Subjects Wi
Unadjusted
BMI-adjusted
BMI, age,* and sex–adj
MV-adjusted†
*Age not included in age-
BMI, systolic blood pressu
medication, triglycerides, d
OR ¼ odds ratio; other a
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914and obese subjects (BMI >25 kg/m2: 5.0% [95% CI:
0.4% to 10.8%]; p ¼ 0.07).
Sex-speciﬁc analysis showed higher CAC progres-
sion per SD of EAT in females compared with males;
however, sex difference did not reach statistical sig-
niﬁcance (age and BMI–adjusted: 6.9% [95% CI: 0.4%
to 13.8%]; p ¼ 0.037 vs. 12.1% [95% CI: 5.0% to 19.7%];
p ¼ 0.0007; for sex interaction: p ¼ 0.12; MV adjusted:
3.8% [95% CI: –2.7% to 10.8%]; p ¼ 0.26 vs. 7.2% [95%
CI: 0.1% to 14.8%]; p ¼ 0.046; for sex interaction: p ¼
0.13, for men and women, respectively). This effect
was explained by different CAC distribution of both
sexes at baseline (detailed data not shown).
To further conﬁrm our results, we assessed the
association of EAT with CAC score at follow-up (log
[CAC(follow-up)þ1]) with CAC score at baseline (log
[CAC(baseline)þ1]) included in the model. Per SD of
EAT, CAC þ 1 at follow-up increased by 7.1% (95% CI:
2.9% to 11.3%; p ¼ 0.0007), independent of CAC score
at baseline. Parameter estimates stayed stable when
further adjusting for age, sex, and BMI (10.4%
[95% CI: 5.5% to 15.5%]; p < 0.001), as well as in
multivariable models (6.2% [95% CI: 1.4% to 11.3%];
p ¼ 0.011).
EAT VOLUME AND CAC ONSET. We further evaluated
the association of EAT with new onset of CAC in the
subset of subjects with CAC ¼ 0 at baselinegression Analysis for the Association of EAT Volume With Onset
th CAC ¼ 0 at Baseline
All Subjects With CAC ¼ 0
at Baseline
Subjects <55 Years of Age
With CAC ¼ 0 at Baseline
OR (95% CI) p Value OR (95% CI) p Value
1.29 (1.11–1.48) 0.0007 1.60 (1.24–2.05) 0.0002
1.21 (1.03–1.43) 0.023 1.54 (1.16–2.03) 0.003
usted 1.07 (0.90–1.27) 0.5 1.52 (1.15–2.01) 0.003
1.01 (0.84–1.21) 0.9 1.37 (1.01–1.85) 0.046
speciﬁc analysis. †MV adjustment included age (not for sex-speciﬁc analysis), sex,
re, antihypertensive medication, LDL cholesterol, HDL cholesterol, lipid-lowering
iabetes, present smoking, and former smoking.
bbreviations as in Tables 1 and 2.examination. Overall, 1,225 subjects (mean age 56.3 
7.2 years, 73% female) had a CAC score of 0 at base-
line. Of those, 307 subjects developed CAC >0 during
follow-up. Subjects with CAC onset had higher
EAT volume at baseline then those with persisting
CAC ¼ 0 (83.8  39.6 ml vs. 73.5  35.3 ml;
p < 0.0001). In univariate logistic regression analysis,
1 SD of EAT was associated with nearly 30% higher
odds of developing CAC, which persisted after
adjustment for BMI (Table 4). When adjusting for age,
sex, and BMI, as well as for established cardiovascular
risk factors, no relevant link between EAT volume
and CAC onset was observed. However, when
stratifying by age at baseline (<55, 55 to <65, and
$65 years of age), we observed a strong association
of EAT with CAC onset in young subjects (<55 years
of age), with 60% higher odds for the development
of CAC per 1 SD of EAT. In contrast, no link was
observed for subjects 55 to <65 years of age (OR:
0.96 [95% CI: 0.75 to 1.23]; p ¼ 0.8) and for subjects
age 65 and older (OR: 1.01 [95% CI: 0.75 to 1.35]; p ¼
0.95). For subjects <55 years of age, the strong
association remained after further adjustment
(Table 4). Sex-speciﬁc analysis revealed no relevant
sex difference for the association of EAT with onset
of CAC (detailed data not shown).
DISCUSSION
In the present analysis, we describe a link between
EAT and progression of CAC as a surrogate marker of
the coronary plaque burden. Although no association
was observed for subjects with heavy calciﬁcation at
baseline, we found a strong link of EAT volume with
CAC progression for subjects with low CAC score at
baseline. Together with the ﬁnding that the observed
correlation between EAT volume and CAC progres-
sion as well as CAC onset was predominantly driven
by subjects in the youngest decade of the investigated
study cohort (45 to 55 years of age), these ﬁndings
support the hypothesis that EAT may inﬂuence the
atherosclerosis process at early stages. Interestingly,
CAC progression was more pronounced in lean sub-
jects, and association of EAT with CAC progression
was independent of BMI, suggesting that quantiﬁca-
tion of EAT volume renders substantially different
information than measurement of overall obesity
despite their distinctive correlation. The present
ﬁndings describe the paracrine impact of this local
visceral adipose tissue on coronary plaque progres-
sion that is different from established mechanisms of
atherosclerosis development.
Over the last decade, several studies investigated a
potential link of epicardial and pericardial adipose
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915tissues with cardiovascular risk factors, coronary
artery plaque burden, and coronary artery disease.
Investigators from the Framingham Heart Study
described an association of EAT with CAC score in a
cross-sectional analysis. However, a signiﬁcant link
was only found when visceral abdominal adipose
tissue was included in the model besides traditional
risk factors; when adjusting for traditional risk factors
alone, the link between EAT and CAC score did not
reach statistical signiﬁcance (1). Likewise, in the
Heinz Nixdorf Recall study, the link of EAT with
CAC score in cross-sectional analysis was ultimately
explained by a shared risk factor proﬁle (6). Besides
calciﬁc coronary atherosclerosis, association of
epicardial and pericardial fat with noncalciﬁed
plaque components was also described (2,8). Ito
et al. (19) reported an association of EAT with
plaque burden and presence of CAD in subjects with
a CAC score of 0, and Schlett et al. (20) found a link
between EAT and CT-derived features of high-risk
plaques. Together with our previous ﬁnding of a
more pronounced association of EAT with future
coronary events in subjects with low or no CAC,
these results support the hypothesis that EAT may
promote atherosclerosis development at early
stages, and therefore, quantiﬁcation of EAT from
cardiac CT may enhance its prognostic value above
coronary anatomy.
The ﬁnding of a stronger link of EAT with CAC
progression in lean subjects is in good agreement
with the current literature. Despite a strong correla-
tion of EAT with BMI and waist circumference, Fra-
mingham investigators also found no attenuation of
effect sizes for the association of EAT with CAC and
prevalent CAD when controlling for these measures of
general adiposity (1,3). When investigating the asso-
ciation of EAT with severity of CAD in 128 subjects
undergoing coronary angiography for evaluation of
angina pectoris, Gorter et al. (21) found that a link
between EAT and CAC and CAD severity was present
only in subjects with a BMI <27 kg/m2. Together
with our ﬁndings, these results suggest that EAT
renders information relevantly differently from
measures of general adiposity, as it may locally
inﬂuence progression of coronary atherosclerosis
above and beyond overall body fat.
The described association between epicardial adi-
pose tissues and coronary plaque burden as well as
presence of coronary heart disease is in part explained
by a strong association of EAT with cardiovascular risk
factors (1,6). However, there is growing evidence that
the correlation of EAT with coronary heart disease
may not fully be explained by risk factors. As further
potential explanation, the endocrine activity ofpericardial fat as visceral adipose tissue, secreting
pro- and anti-inﬂammatory mediators and cytokines
such as adiponectin, Il-6, and TNFa, is discussed in
the literature (22–25). The amount of adiponectin, a
stabilizer of the inhibitor of NF-kappa B released from
pericardial fat (26), decreases with an increased
amount of fat (27). The decrease of adiponectin
enhances the activity of NF-kappa B, which leads to
an increase in TNFa and, hence, to a local increase of
inﬂammation (26). A mismatch of pro- and anti-
inﬂammatory mediators and cytokines secreted by
EAT is suspected to have a local inﬂuence on the
underlying coronary arteries. Increased CD45
messenger ribonucleic acid expression in the EAT of
subjects with coronary artery disease, representing
elevated macrophage inﬁltration, and an increase of
mast cells in the adventitia of coronary lesions has
been observed (22,23,28). The hypothesis of a local
and speciﬁc inﬂuence of EAT in coronary ath-
erosclerosis is supported by our ﬁndings of the
association of EAT with progression of coronary
calciﬁcation independent of overall adiposity,
despite its relatively small size compared to visceral
abdominal or subcutaneous fat.
STUDY LIMITATIONS. Strengths of our study include
the population-based design without selection of
the cohort to adiposity-related traits. Traditional
cardiovascular risk factors were measured using
highly standardized protocols, and EAT was quanti-
ﬁed using a reproducible volume-based method.
Likewise, the same scanner technology and identical
scanning protocols were used for repetitive cardiac
CT measurement at initial enrollment and after 5
years of follow-up. Moreover, a potential bias by
therapy was not possible because participants and
their physicians were blinded to the results of the
CAC scoring from the baseline examination. As a
limitation, application of contrast media was not
possible due to the population-based study design.
Therefore, we were unable to detect noncalciﬁed
plaque components and are not able to make any
conclusion on whether EAT may lead to progression
of vulnerable plaques. Baseline CAC score is a pre-
dictor of CAC progression. Therefore, analysis of EAT
on CAC progression may be impacted by baseline
CAC. However, we performed several additional ap-
proaches including analyses in subgroups of CAC
score at baseline, which conﬁrmed the results. As a
further limitation, our study is based on a predomi-
nantly Caucasian population; hence, generalizability
to other ethnic groups remains uncertain. Last, in our
analysis, we excluded subjects with revasculariza-
tion during follow-up due to uncertainties on the
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916quantiﬁcation of CAC after stent implantation or
bypass surgery, which may have led to a selection
bias.
CONCLUSIONS
EAT volume is associated with CAC progression after
5 years, especially in young subjects and subjects
with low CAC score at baseline, independent oftraditional cardiovascular risk factors. These ﬁndings
support the hypothesis that EAT promotes early
atherosclerosis development.
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